argenx SE ("argenx") announced the trading of the initial public offering (the "IPO") of a total of 6,744,750 American Depository Receipts ("ADSs") worth approximately USD 114.7 million on the NASDAQ Global Stock Market (including greenshoe). argenx has been listed on the Brussels Stock Exchange since June 2014. Each ADS represents the right to receive one underlying ordinary share, which ordinary share will be listed on the Brussels Stock Exchange.
argenx is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases and is one of the biggest public biotechs in each European country in which it operates. Proceeds from the transaction will be used to finance current and future research, clinical and technical development of several therapeutic antibodies (ARGX-113 and ARGX-110), working capital and other general corporate purposes.
The offices of NautaDutilh Amsterdam and NautaDutilh Brussels successfully acted as Belgian and Dutch counsel, alongside Cooley LLP, who acted as US Counsel on this Nasdaq IPO. As argenx recently converted from a Dutch NV into a European SE with its corporate seat in the Netherlands, the deal team faced several legal and practical cross border challenges and resolved due to excellent teamwork between our offices in Amsterdam and Brussels.
Cowen and Company and Piper Jaffray & Co. acted as joint bookrunning managers on this transaction. JMP Securities and Wedbush PacGrow acted as co-managers.
The NautaDutilh team consisted of Petra Zijp, Nicolas de Crombrugghe, Antonia Netiv, Philippine de Wolf, Pieter van Drooge, Dewi Walian, Nina Kielman, Sabrina Legerstee and Louis Lantonnois.